Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Catalent Revenues up 4% in the Quarter | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Catalent Revenues up 4% in the Quarter

Biologics revenue up 3% and Pharma and Consumer Health revenue up 5%.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent
1Q Revenues: $1.02 billion (+4%)
1Q Loss: $129 million (loss of $759 million Fiscal 1Q24)
Comments: Biologics revenue was $461 million in the quarter, up 3%. Pharma and Consumer Health revenues were $563, up 5%. After excluding COVID-related revenue of approximately $30 million in the first quarter of fiscal 2025 and approximately $100 million in first quarter of fiscal 2024, net revenue increased 13%.
 
The merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction for $16.5 billion, is expected to close at end of 2024, subject to customary closing conditions.

Related News: Catalent Issues Letter Regarding Pending Acquisition by Novo Holdings

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters